{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:18:40Z","timestamp":1764058720327,"version":"3.45.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103740","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:34:58Z","timestamp":1760099698000},"page":"103740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibiting silencing information regulator 1 is conducive to the suppression of hepatitis B virus replication by entecavir"],"prefix":"10.1016","volume":"392","author":[{"given":"Xueying","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6506-2235","authenticated-orcid":false,"given":"Fumin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103740_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2014.04.026","article-title":"The role of Kupffer cells in hepatitis B and hepatitis C virus infections","volume":"61","author":"Boltjes","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib2","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/v16050707","article-title":"The adaptive immune response in hepatitis B virus-associated hepatocellular carcinoma is characterized by dysfunctional and exhausted HBV-specific T cells","volume":"16","author":"Broholm","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jpet.2025.103740_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/17474124.2023.2212161","article-title":"Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis","volume":"17","author":"Liu","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jpet.2025.103740_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jpet.2025.103740_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jpet.2025.103740_bib9","article-title":"Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA","volume":"12","author":"Ren","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.jpet.2025.103740_bib10","doi-asserted-by":"crossref","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","article-title":"Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation","volume":"112","author":"Tropberger","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2025.103740_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jpet.2025.103740_bib12","article-title":"Effect of the deubiquitinating peptidase 7 (USP7) on hepatitis B virus (HBV) replication and the antiviral efficacy of entecavir (ETV)","author":"Liu","year":"2024","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.jpet.2025.103740_bib13","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1042\/CS20210392","article-title":"SIRT7 restricts HBV transcription and replication through catalyzing desuccinylation of histone H3 associated with cccDNA minichromosome","volume":"135","author":"Yu","year":"2021","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.jpet.2025.103740_bib14","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s12250-017-4009-4","article-title":"Recent advances in the study of hepatitis B virus covalently closed circular DNA","volume":"32","author":"Ji","year":"2017","journal-title":"Virol Sin"},{"key":"10.1016\/j.jpet.2025.103740_bib15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mc.22946","article-title":"Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1\/Ac-p53 regulatory axis","volume":"58","author":"Pant","year":"2019","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.jpet.2025.103740_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110939","article-title":"Silencing SIRT1 promotes the anti-HBV action of IFN-\u03b1 by regulating Pol expression and activating the JAK-STAT signaling pathway","volume":"124","author":"Tang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jpet.2025.103740_bib17","article-title":"Regulation of SIRT1 and its roles in inflammation","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103740_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbagrm.2017.02.007","article-title":"Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription","volume":"1860","author":"Deng","year":"2017","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"10.1016\/j.jpet.2025.103740_bib19","doi-asserted-by":"crossref","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jpet.2025.103740_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1517\/14656566.2016.1118056","article-title":"Pharmacotherapeutic options for hepatitis B","volume":"17","author":"Chen","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpet.2025.103740_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00705-015-2712-8","article-title":"The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo","volume":"161","author":"Li","year":"2016","journal-title":"Arch Virol"},{"key":"10.1016\/j.jpet.2025.103740_bib22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1093\/hmg\/ddt556","article-title":"SIRT2 regulates ciliogenesis and contributes to abnormal centrosome amplification caused by loss of polycystin-1","volume":"23","author":"Zhou","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jpet.2025.103740_bib23","first-page":"Ol1737","article-title":"Transcription levels of sirtuin family in neural stem cells and brain tissues of adult mice","volume":"Suppl.58","author":"Wang","year":"2012","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"10.1016\/j.jpet.2025.103740_bib24","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3389\/fimmu.2019.02048","article-title":"HBV-induced immune imbalance in the development of HCC","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103740_bib25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/v12070746","article-title":"The multiple roles of hepatitis B virus X protein (HBx) dysregulated MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways","volume":"12","author":"Sartorius","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jpet.2025.103740_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrgastro.2016.7","article-title":"Global strategies are required to cure and eliminate HBV infection","volume":"13","author":"Revill","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1743-422X-11-165","article-title":"Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion","volume":"11","author":"Yang","year":"2014","journal-title":"Virol J"},{"key":"10.1016\/j.jpet.2025.103740_bib28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","author":"Huang","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jpet.2025.103740_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van B\u00f6mmel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jpet.2025.103740_bib30","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1128\/JVI.02861-13","article-title":"Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1","volume":"88","author":"Ren","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.jpet.2025.103740_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2016.08.007","article-title":"Suppression of hepatitis B virus antigen production and replication by wild-type HBV dependently replicating HBV shRNA vectors in vitro and in vivo","volume":"134","author":"Li","year":"2016","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jpet.2025.103740_bib32","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14218\/JCTH.2015.00024","article-title":"IL-6 plays a crucial role in HBV infection","volume":"3","author":"Lan","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jpet.2025.103740_bib33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1462-5822.2008.01280.x","article-title":"Repression of hepatitis B viral gene expression by transcription factor nuclear factor-kappaB","volume":"11","author":"Lin","year":"2009","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.jpet.2025.103740_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40257-019-00457-3","article-title":"Managing psoriasis in patients with HBV or HCV infection: practical considerations","volume":"20","author":"Piaserico","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jpet.2025.103740_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.intimp.2018.11.054","article-title":"SIRT1 alleviates isoniazid-induced hepatocyte injury by reducing histone acetylation in the IL-6 promoter region","volume":"67","author":"Zhang","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jpet.2025.103740_bib36","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jpet.2025.103740_bib37","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","article-title":"The sirtuin family in health and disease","volume":"7","author":"Wu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jpet.2025.103740_bib38","first-page":"634","article-title":"miR-217 and miR-543 downregulation mitigates inflammatory response and myocardial injury in children with viral myocarditis by regulating the SIRT1\/AMPK\/NF-\u03baB signaling pathway","volume":"45","author":"Xia","year":"2020","journal-title":"Int J Mol Med"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:16:25Z","timestamp":1764058585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402535"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103740","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting silencing information regulator 1 is conducive to the suppression of hepatitis B virus replication by entecavir","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103740"}}